Tobacco smoking is associated with antipsychotic medication, physical aggressiveness, and alcohol use disorder in schizophrenia: results from the FACE-SZ national cohort.
Eur Arch Psychiatry Clin Neurosci. 2018-02-02; 269(4): 449-457
DOI: 10.1007/s00406-018-0873-7
Read on PubMed
1. Eur Arch Psychiatry Clin Neurosci. 2019 Jun;269(4):449-457. doi:
10.1007/s00406-018-0873-7. Epub 2018 Feb 2.
Tobacco smoking is associated with antipsychotic medication, physical
aggressiveness, and alcohol use disorder in schizophrenia: results from the
FACE-SZ national cohort.
Mallet J(1)(2)(3)(4)(5), Le Strat Y(6)(7)(8)(9)(10), Schürhoff F(6)(11)(12),
Mazer N(6)(7)(8)(9)(10), Portalier C(6)(7)(8)(9)(10), Andrianarisoa
M(6)(11)(12), Aouizerate B(6)(13)(14)(15)(16), Berna F(6)(17), Brunel
L(6)(11)(12), Capdevielle D(6)(18), Chereau I(6)(19), D’Amato T(6)(20), Dubreucq
J(6)(21), Faget C(6)(22), Gabayet F(6)(21), Honciuc RM(6)(19), Lançon C(6)(23),
Llorca PM(6)(19), Misdrahi D(6)(13)(14)(24), Rey R(6)(20), Roux P(6)(25),
Schandrin A(6)(18), Urbach M(6)(25), Vidailhet P(6)(17), Fond G(6), Dubertret
C(6)(7)(8)(9)(10); FACE-SZ (FondaMental Academic Centers of Expertise for
Schizophrenia) group.
Collaborators: Andrianarisoa M, Aouizerate B, Bazin N, Berna F, Blanc O, Brunel
L, Bulzacka E, Capdevielle D, Chereau-Boudet I, Chesnoy-Servanin G, Nathalie C,
Danion JM, D’Amato T, Deloge A, Delorme C, Denizot H, Dorey JM, Dubertret C,
Dubreucq J, Faget C, Fluttaz C, Fond G, Fonteneau S, Gabayet F, Giraud-Baro E,
Lacelle D, Lançon C, Laouamri H, Leboyer M, Le Gloahec T, Le Strat Y, Llorca PM,
Mallet J, Metairie E, Misdrahi D, Offerlin-Meyer I, Passerieux C, Peri P, Pires
S, Portalier C, Ramet L, Rey R, Roman C, Schandrin A, Schürhoff F, Tessier A,
Tronche AM, Urbach M, Vaillant F, Vehier A, Vidailhet P, Vilà E, Yazbek H,
Zinetti-Bertschy A.
Author information:
(1)Fondation FondaMental, Créteil, France. .
(2)AP-HP, Paris, France. .
(3)Department of Psychiatry, Service de Psychiatrie et d’Addictologie, Hôpital
Louis Mourier, 178 rue des Renouillers, 92700, Colombes, France.
.
(4)Inserm U894, Paris, France. .
(5)Sorbonne Paris Cité, Faculté de Médecine, Université Paris Diderot, Paris,
France. .
(6)Fondation FondaMental, Créteil, France.
(7)AP-HP, Paris, France.
(8)Department of Psychiatry, Service de Psychiatrie et d’Addictologie, Hôpital
Louis Mourier, 178 rue des Renouillers, 92700, Colombes, France.
(9)Inserm U894, Paris, France.
(10)Sorbonne Paris Cité, Faculté de Médecine, Université Paris Diderot, Paris,
France.
(11)INSERM U955, Équipe de Psychiatrie Translationnelle, Créteil, France.
(12)Université Paris-Est Créteil, DHU Pe-PSY, Pôle de Psychiatrie des Hôpitaux
Universitaires H Mondor, Créteil, France.
(13)Centre Hospitalier Charles Perrens, 33076, Bordeaux, France.
(14)Université de Bordeaux, Bordeaux, France.
(15)Bordeaux Sleep Clinique, Pellegrin University Hospital, Bordeaux University,
USR CNRS 3413 SANPSY, Research Unit, 33000, Bordeaux, France.
(16)Inserm, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale,
U862, 33000, Bordeaux, France.
(17)Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, INSERM
U1114, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg,
France.
(18)Service Universitaire de Psychiatrie Adulte, Hôpital la Colombière, CHRU
Montpellier, Université Montpellier 1, Inserm 1061, Montpellier, France.
(19)CMP B, CHU, EA 7280 Faculté de Médecine, Université d’Auvergne, BP 69 63003,
Clermont-Ferrand Cedex 1, France.
(20)INSERM U1028, CNRS UMR5292, Centre de Recherche en Neurosciences de Lyon,
Université Claude Bernard Lyon 1, Equipe PSYR2, Centre Hospitalier Le Vinatier,
Pole Est, 95 bd Pinel, BP 30039, 69678, Bron Cedex, France.
(21)Centre Référent de Réhabilitation Psychosociale, CH Alpes Isère, Grenoble,
France.
(22)Pôle Psychiatrie Universitaire, CHU Sainte-Marguerite, 13274, Marseille
Cedex 09, France.
(23)Assistance Publique des Hôpitaux de Marseille (AP-HM), Pôle Universitaire de
Psychiatrie, Marseille, France.
(24)CNRS UMR 5287-INCIA, Bordeaux, France.
(25)Service de psychiatrie d’adulte, Centre Hospitalier de Versailles, UFR des
Sciences de la Santé Simone Veil, Université Versailles Saint-Quentin en
Yvelines, Versailles, France.
Tobacco smoking is common in schizophrenia and is one of the main causes of
premature mortality in this disorder. Little is known about clinical correlates
and treatments associated with tobacco smoking in patients with schizophrenia.
Still, a better characterization of these patients is necessary, in a
personalized care approach. Aggressiveness and childhood trauma have been
associated with tobacco smoking in general population, but this association has
never been explored in schizophrenia. Our study examines the clinical and
therapeutic characteristics of tobacco smoking in schizophrenia. 474 stabilized
patients (mean age = 32.2; 75.7% male gender; smokers n = 207, 54.6%) were
consecutively included in the network of the FondaMental Expert centers for
Schizophrenia and assessed with valid scales. Current tobacco status was
self-declared. Aggressiveness was self-reported with Buss-Perry Aggressiveness
Questionnaire and Childhood Trauma with Childhood Trauma Questionnaire. Ongoing
treatment was reported. In univariate analysis, tobacco smoking was associated
with lower education level (p